

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
Tommy Douglas Conference Center  
10000 New Hampshire Avenue, Silver Spring, Maryland 20903  
September 14, 2016

**DRAFT MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Lauren D. Tesh, PharmD, BCPS**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA  
Silver Spring, Maryland

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Harold J. Burstein, MD, PhD**

Senior physician, Dana-Farber Cancer Institute  
Associate Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts

**Bernard F. Cole, PhD**

Professor  
Department of Mathematics and Statistics  
University of Vermont  
Burlington, Vermont

**Grzegorz S. Nowakowski, MD**

Assistant Professor of Medicine  
Mayo Clinic Rochester  
Rochester, Minnesota

**Vassiliki Papadimitrakopoulou, MD**

Professor of Medicine  
Thoracic/Head and Neck Medical Oncology  
MD Anderson Cancer Center  
Houston, Texas

**Gregory J. Riely, MD, PhD**

Associate Attending  
Memorial Sloan Kettering Cancer Center  
Associate Professor, Weill Cornell Medical College  
New York, New York

**Brian I. Rini, MD, FACP**

Professor of Medicine  
Cleveland Clinic Taussig Cancer Institute  
Glickman Urological and Kidney Institute  
Cleveland, Ohio

**Bruce J. Roth, MD**

*(Chairperson)*  
Professor of Medicine  
Division of Oncology  
Washington University School of Medicine  
St. Louis, Missouri

**Thomas S. Uldrick, MD, MS**

Clinical Director  
HIV & AIDS Malignancy Branch, Center for Cancer  
Research  
National Cancer Institute  
Bethesda, Maryland

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Phuong Khanh (P.K.) Morrow, MD, FACP**

*(Industry Representative)*  
Executive Medical Director, Amgen Oncology  
Therapeutic Area Head, US Medical Organization  
Thousand Oaks, California

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
September 14, 2016

**DRAFT MEETING ROSTER (cont.)**

---

**TEMPORARY MEMBERS (Voting)**

**Karim Chamie, MD, MSHS**

Assistant Professor of Urology  
Department of Urology  
University of California, Los Angeles  
Los Angeles, California

**Pamela J. Haylock, PhD, RN**

*(Consumer Representative)*  
Adjunct Faculty, Sul Ross State University  
Alpine, Texas  
Oncology Nursing Educator  
Medina, Texas

**Patricia A. Spears**

*(Patient Representative)*  
Raleigh, North Carolina

**John A. Taylor, III, MD, MS**

Professor of Urology  
Co-Director, Drug Development Discovery &  
Experimental Therapeutics  
University of Kansas Medical Center  
Kansas City, Kansas

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director  
Office of Hematology and Oncology Products  
(OHOP)  
Office of New Drugs (OND), CDER, FDA

**Ellen Maher, MD**

Medical Team Leader  
Genitourinary Cancers Team  
DOP1, OHOP, OND, CDER, FDA

**Mark L. Gonzalgo, MD, PhD**

Professor  
Department of Urology  
University of Miami Miller School of Medicine  
Miami, Florida

**Brent Logan, PhD**

Professor and Director  
Division of Biostatistics  
Medical College of Wisconsin  
Milwaukee, Wisconsin

**Jennifer M. Taylor, MD, MPH**

Assistant Professor, Urology  
Baylor College of Medicine  
Michael E. DeBakey VA Medical Center  
Houston, Texas

**Geoffrey Kim, MD**

Director  
Division of Oncology Products 1 (DOP1)  
OHOP, OND, CDER, FDA

**Gwynn Ison, MD**

Medical Officer  
DOP1, OHOP, OND, CDER, FDA

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Oncologic Drugs Advisory Committee (ODAC) Meeting*  
September 14, 2016

**DRAFT MEETING ROSTER (cont.)**

---

**FDA PARTICIPANTS (Non-Voting) (cont.)**

**Chana Weinstock, MD**

Medical Officer  
Genitourinary Cancers Team  
DOP1, OHOP, OND, CDER, FDA

**Erik Bloomquist, PhD**

Statistical Reviewer  
Division of Biometrics V (DBV)  
Office of Biometrics (OB)  
Office of Translational Sciences (OTS)  
CDER, FDA

DRAFT